MergerMay 7, 2026, 08:52 AM
Catalyst Pharma Acquired by Angelini for $31.50/Share, $4.1B Total
AI Summary
Catalyst Pharmaceuticals, Inc. will be acquired by Angelini Pharma S.p.A. for $31.50 per share in cash, totaling approximately $4.1 billion. This represents a 28% premium to Catalyst's 30-day volume-weighted average trading price as of April 22, 2026. The transaction, unanimously approved by both boards, is expected to close in the third quarter of 2026, facilitating Angelini Pharma's entry into the U.S. market and bolstering its rare disease portfolio. Additionally, Catalyst resolved its FIRDAPSE patent litigation with Hetero Labs Ltd., allowing generic market entry no earlier than January 2035.
Key Highlights
- Catalyst Pharmaceuticals to be acquired by Angelini Pharma for approximately $4.1 billion.
- Shareholders will receive $31.50 per share in cash.
- The acquisition price represents a 28% premium to the 30-day VWAP as of April 22, 2026.
- The transaction is expected to close in the third quarter of 2026.
- Catalyst resolved FIRDAPSE patent litigation with Hetero Labs Ltd.
- Hetero Labs Ltd. is licensed to market generic FIRDAPSE starting January 2035.